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stable, responsive to persistent toxin therapy for ≥1 year
before and after drug crossover, did not receive other
medications that affect neuromuscular transmission, 
and were not involved in another drug study. Mean 
per-patient, per-visit and total toxin dose, dosing ratio
(Dysport: BOTOX), and frequencies of adverse drug reac-
tions (ADRs) were computed along with break-even drug
cost equivalence in 5 of 6 participating sites. RESULTS:
One hundred fourteen screen-qualiﬁed patients (70 cervi-
cal dystonia, 44 blepharospasm) were assessed, providing
1,399 injections for evaluation. Ratios of mean dose
(units) Dysport: BOTOX ranged from 2 :1 to 11 :1, with
88% of patients greater than 3 :1, regardless of study site
or direction of drug cross-over. ADRs were more fre-
quently reported during Dysport treatment (11%) than
during BOTOX treatment (4.25%). Drug unit cost equiv-
alence (Dysport to BOTOX) based on local pricing were
2.0 :1 for the Czech Republic, 3.91 :1 in the UK (Hull and
Essex), 4.16 :1 in Slovenia, and 5.24 :1 in Poland. When
observed mean dose ratios were compared to cost equiv-
alent ratios, the proportion of patients that would con-
tribute to cost savings if BOTOX were exclusively utilized
is 63%. CONCLUSION: BOTOX utilization likely leads
to cost savings, based on utilization and current pricing
compared to Dysport. When other important considera-
tions such as ADRs are considered, overall savings may
be even greater.
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OBJECTIVES: To carry out a systematic review of the
published literature that compares the cost-effectiveness
of newer hypnotic drugs (zolpidem, zopiclone and zale-
plon) with more established hypnotic drugs (benzodi-
azepines). The aim of this review was to identify
economic evaluations that had been undertaken in the
context of high quality randomised controlled trials in
order to inform UK NHS decision-making. METHODS:
The search included a number of strategies. Search terms
for electronic databases (MEDLINE, EMBASE, HTA,
DARE, NHSEED, OHE-EED, Cochrane Trials Register)
included a combination of index terms (e.g. sleep initia-
tion and maintenance disorders or insomnia) and free text
words (e.g. insomnia or sleeplessness) combined with spe-
ciﬁc drug terms (e.g. zaleplon or sonata, zolpidem or stil-
noct). Clinical terms were combined with economic terms
(e.g. cost or economic). After scanning the abstracts, all
papers that appeared to be of potential value to the study
were obtained. Using explicit, predetermined criteria, two
reviewers independently identiﬁed studies for inclusion in
the cost-effectiveness review process. Disagreements were
resolved through discussion. RESULTS: Although a large
number of papers (n = 925) was identiﬁed by the cost-
effectiveness search strategies, only 33 were assessed for
inclusion in the review, none of which met the inclusion
criteria. No full economic evaluations alongside ran-
domised controlled trials were identiﬁed either between
or across drug groups. Consequently the results of this
literature search did not lead to the identiﬁcation of any
papers for inclusion in the review. CONCLUSIONS: The
burden of disease associated with insomnia is signiﬁcant.
However, there is a paucity of published economic evi-
dence to support NHS decision-making in this area. It 
is imperative that economic evaluations alongside ran-
domised clinical trials be conducted in order to build a
clinical and economic evidence base to inform decision-
making not only in the UK, but also throughout the
world.
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OBJECTIVES: To identify and evaluate resource utiliza-
tion and related costs of SCI patients after initial reha-
bilitation. Both direct (devices, modiﬁcations of home or
workplace) and indirect (lost productivity) costs were
included and evaluated. METHODS: This was a mono-
center, retrospective chart-review study supplemented
with phone interviews to collect information on home
and workplace modiﬁcations. The last 200 consecutive
patients from the Berufsgenossenschaftliche Unfallklinik
Hamburg, Germany fulﬁlling in- and exclusion criteria
(most importantly: age 18–35, SCI at C6 or below). End-
points: Ability to work, actual working patterns, need
and costs of home and workplace modiﬁcations, need,
and costs of professional help for ADLs, costs of mo-
bility devices. A societal perspective was adopted.
RESULTS: Total cost from an societal perspective per
person in this study was €32,517 (19% devices, 10% pro-
fessional help, 22% home modiﬁcations, 49% indirect
costs) in the ﬁrst year and is estimated at €19,186 for the
following years. This does not include cost for workplace
modiﬁcations for which no reliable data could be col-
lected. However, it may be reasonable to assume this cost
to be in the same order of magnitude as the costs for home
modiﬁcations. Average yearly transfer payments (rent and
social welfare) were estimated at €7301 for each patient.
CONCLUSIONS: Indirect costs are the major cost driver
for SCI-patients, in particular after the ﬁrst year when
initial payments for devices and home modiﬁcations are
done. Investments to increase the share of working
persons with SCI (e.g. by improving mobility and acces-
